Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerivio REN for Pediatric Migraine in the ED
NCT05102591Phase 3Completed
- Sponsor
- University of Calgary
- Start
- Feb 2022
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine, sponsored by University of Calgary. Primary endpoint: Assessment of Recruitment Rate at 2 years. Started Feb 2022; status: completed.
02
Conditions
migraine
Beyond the preview
Go deeper on NCT05102591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05102591.